Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant

References

• Broxmeyer HE, Douglas GW, Hangoc G, . Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828–3832.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Laughlin M, Graham ML, . Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157–166.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Barker JN, DeFor TE, . Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611–1618.
   PubMed Web of Science ®Google Scholar
• Laughlin MJ, Barker J, Bambach B, . Hematopoietic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors. N Engl J Med 2001;344:1815–1822.
   PubMed Web of Science ®Google Scholar
• Long GD, Laughlin M, Madan B, . Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 2003;9:772–780.
   PubMed Web of Science ®Google Scholar
• Rubinstein P, Carrier C, Scaradavou A, . Outcomes among 562 recipients of placental blood transplants from unrelated donors. N Engl J Med 1998;339:1565–1577.
   PubMed Web of Science ®Google Scholar
• Barker JN, Weisdorf DJ, DeFor TE, . Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343–1347.
   PubMed Web of Science ®Google Scholar
• Giralt S, Thall PF, Khouri I, . Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631–637.
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naperstek E, . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant diseases. Blood 1998;91:756–763.
   PubMed Web of Science ®Google Scholar
• Sanz J, Sanz MA, Saavedra S, . Cord blood transplantation from unrelated donors in adults with high risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010;16:86–94.
   PubMed Web of Science ®Google Scholar
• Rubinstein P, Dobrila L, Rosenfield RE, . Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995;92:10119–10122.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Martin P, Klingmann HG, . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–828.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Agura E, Anasetti C, . Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250–259.
   PubMed Web of Science ®Google Scholar
• Common Toxicity Criteria. Version 3.0. Available from: http://ctep.info.nih.gov/reporting/ctc.html
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Prentice RL, Kalbfleisch JD, Peterson AV, . The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541–554.
   PubMed Web of Science ®Google Scholar
• Agresti A. A survey of exact inference for contingency tables. Stat Sci 1992;7:131–153.
   Google Scholar
• Cox DR. Regression models and life tables [with discussion]. J R Stat Soc B 1972;34:187–202.
   Google Scholar
• de Lima M, McMannis J, Gee A, . Transplantation on ex vivo expanded cord blood cells using copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008; 41:771–778.
   PubMed Web of Science ®Google Scholar
• de Lima M, Robinson S, McMannis J, . Mesenchymal stem cell (MSC) based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils. Blood 2010;116(Suppl. 1): Abstract 362.
   Google Scholar
• Ciurea SO, de Lima M, Cano P, . High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem cell transplantation. Transplantation 2009;88:1019–1024.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Saliba R, Rondon G, . Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 2010;45:429–436.
   PubMed Web of Science ®Google Scholar
• Lekakis L, Giralt S, Couriel D, . Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant 2006;38:421–426.
   PubMed Web of Science ®Google Scholar
• Narimatsu H, Watanabe M, Kohno A, . High incidence of graft failure in unrelated cord blood transplantation using reduced-intensity preparative regimen consisting of fludarabine and melphalan. Bone Marrow Transplant 2008;41:753–756.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Morris A, Gasparetto C, . Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008;14:591–594.
   PubMed Web of Science ®Google Scholar
• Komanduri K, St John LS, de Lima M, . Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007;110:4543–4551.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Mulanovich V, Jiang Y, . Lymphocyte recovery predicts outcomes in cord blood and T-cell depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2010;17:1169–1175.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Weisdorf DJ, DeFor T, . Increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006;108:2874–2880.
   PubMed Web of Science ®Google Scholar
• Ballen KK, Cutler C, Yeap BY, . Donor-derived second malignancies after cord blood transplantation. Biol Blood Marrow Transplant 2010;16:1025–1031.
   PubMed Web of Science ®Google Scholar